Frontlight ResearchEarly access
Taking people in United StatesPhase 1/2
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
Key facts
- Who runs it
- New York Medical College
- Where
- Baltimore, Columbus, Milwaukee, Philadelphia, San Francisco, St Louis, and Vallhala, United StatesSee the 7 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 40 people, planned
- Started
- 1 Jul 2020
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Treatments tested
- BK CTL
- Record updated
- 15 April 2026
Who can take part
- Age
- 1 month to 79 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- .1.1 Patients with refractory BK infection post allogeneic HSCT, post solid organ transplantation or with primary immunodeficiencies with either
- Increasing urine and/or plasma BK RT-PCR DNA (by 1 log) after 7 days or persistent quantitative qRT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy AND/OR
- Medical intolerance to anti-viral therapies including:; 2 renal toxicity with cidofovir or other > grade 2 toxicities secondary to cidofovir And/or
- known resistance to cidofovir 1.2. Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures; 1.3 Performance Status > 30% (Lansky < 16 yrs and Karnofsky > 16 yrs) 1.4 Age: 0.1 to 79.99 years 1.5 Females of childbearing potential with a negative urine pregnancy test; Exclusion:
- Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of BK CTL infusion
- Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of BK CTL infusion
- Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to BK CTL infusion
- Thymoglobulin (ATG) or Alemtuzumab within 30 days
- Patient with poor performance status determined by Karnofsky (patients >16 years) or Lansky (patients ≤16 years) score ≤30%
- Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory BK infection
- Any medical condition which could compromise participation in the study according to the investigator's assessment
- Known HIV infection
- Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment
- Known hypersensitivity to iron dextran
- Patients unwilling or unable to comply with the protocol or unable to give informed consent
- Known human anti-mouse antibodies
Where in United States
- Johns HopkinsBaltimore, United StatesContact: Kenneth Cooke, MDTaking people
- Nationwide Children's HosptialColumbus, United StatesContact: Dean Lee, MD, PhDTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Julie A Talano, MDTaking people
- Children's Hospital of PennsylvaniaPhiladelphia, United StatesContact: Nancy Bunin, MDTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Julia Chu, MDTaking people
- Washington UniversitySt Louis, United StatesContact: Shalini Shenoy, MDTaking people
- New York Medical CollegeVallhala, United StatesContact: Mitchell S Cairo, MDTaking people
About the trial
What the trial wants to find out
BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).
The group in the trial
- BK CTLTreatment being tested
Eligible patients with refractory BK infection will receive up to 20 infusions of BK CTLs that are donor derived.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study in the Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients
- Record updated
- 15 April 2026